Studies on the alpha-glucoside hydrolase inhibitor, adiposin. III. alpha Glucoside hydrolase inhibitory activity and antibacterial activity in vitro. 1982

K Kangouri, and S Namiki, and T Nagate, and H Hara, and K Sugita, and S Omura

Adiposin-1 and -2 exhibited potent inhibitory activities against alpha-amylase, human salivary alpha-amylase and disaccharidases isolated from porcine small intestine. The effect of adiposin-1 and -2 on hydrolysis of glucoamylase was non-competitive. Adiposin showed antimicrobial activities against some Gram-positive bacteria, Gram-negative bacteria belonging to Enterobacteriaceae, Some anaerobic bacteria and some phytopathogenic fungi, and showed a synergistic effect on the antibacterial activity with some maltooligosaccharides. However, these antibacterial activities were suppressed by addition of various other saccharides.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D004187 Disaccharides Oligosaccharides containing two monosaccharide units linked by a glycosidic bond. Disaccharide
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005658 Fungi A kingdom of eukaryotic, heterotrophic organisms that live parasitically as saprobes, including MUSHROOMS; YEASTS; smuts, molds, etc. They reproduce either sexually or asexually, and have life cycles that range from simple to complex. Filamentous fungi, commonly known as molds, refer to those that grow as multicellular colonies. Fungi, Filamentous,Molds,Filamentous Fungi,Filamentous Fungus,Fungus,Fungus, Filamentous,Mold
D006026 Glycoside Hydrolases Any member of the class of enzymes that catalyze the cleavage of the glycosidic linkage of glycosides and the addition of water to the resulting molecules. Endoglycosidase,Exoglycosidase,Glycohydrolase,Glycosidase,Glycosidases,Glycoside Hydrolase,Endoglycosidases,Exoglycosidases,Glycohydrolases,Hydrolase, Glycoside,Hydrolases, Glycoside
D000606 Amino Sugars SUGARS containing an amino group. GLYCOSYLATION of other compounds with these amino sugars results in AMINOGLYCOSIDES. Amino Sugar,Sugar, Amino,Sugars, Amino
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria

Related Publications

K Kangouri, and S Namiki, and T Nagate, and H Hara, and K Sugita, and S Omura
January 1978, Lancet (London, England),
K Kangouri, and S Namiki, and T Nagate, and H Hara, and K Sugita, and S Omura
April 1981, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
K Kangouri, and S Namiki, and T Nagate, and H Hara, and K Sugita, and S Omura
August 1995, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
K Kangouri, and S Namiki, and T Nagate, and H Hara, and K Sugita, and S Omura
March 1984, Diabetes,
K Kangouri, and S Namiki, and T Nagate, and H Hara, and K Sugita, and S Omura
September 1975, Arzneimittel-Forschung,
K Kangouri, and S Namiki, and T Nagate, and H Hara, and K Sugita, and S Omura
January 1965, Chemotherapy,
K Kangouri, and S Namiki, and T Nagate, and H Hara, and K Sugita, and S Omura
November 1967, Minerva medica,
K Kangouri, and S Namiki, and T Nagate, and H Hara, and K Sugita, and S Omura
April 1982, The Journal of antibiotics,
K Kangouri, and S Namiki, and T Nagate, and H Hara, and K Sugita, and S Omura
January 2003, Anti-cancer drugs,
K Kangouri, and S Namiki, and T Nagate, and H Hara, and K Sugita, and S Omura
April 2004, The Journal of antimicrobial chemotherapy,
Copied contents to your clipboard!